Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron

“The Regeneron-Sanofi alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster.”

Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron

“By expanding our alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”

Belén Garijo, Chief Executive Officer of Sanofi

“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses.”

Belén Garijo, Chief Executive Officer of Sanofi

“By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”

George D. Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron

“The companies’ clinical and commercial alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide.”

George D. Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron

“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”